Vik Chandra, CEO of uMETHOD, talked with Fox News Digital about how his company's AI tool, RestoreU, is helping physicians pinpoint better treatment plans for their dementia patients. More than six million Americans are living with Alzheimer's disease -- and one in three seniors dies with the disease, according to statistics from the Alzheimer's Association. With so many different factors -- genetics, lifestyle and environment -- influencing a person's risk of developing Alzheimer's, many doctors are moving away from one-size-fits-all approaches and calling for more individualized treatments. It's a concept known as precision medicine. And it's what inspired a company called uMETHOD to create RestoreU, a tool that uses artificial intelligence to help physicians create personalized care plans for patients with Alzheimer's and other types of dementia.

Every week, Q.ai releases a thematic screen, courtesy of the Forbes AI Investor platform. With real-time insights and our proprietary internal ratings system – not to mention our artificial intelligence unit – we provide the data you need to build your portfolio in the long-term. This week, our thematic focus is on Quality Value. Q.ai runs factor models daily to get the most up-to-date reading on stocks and ETFs. Our deep-learning algorithms use Artificial Intelligence (AI) technology to provide an in-depth, intelligence-based look at a company – so you don't have to do the digging yourself.

Quest Diagnostics, a provider of diagnostic information services, and hc1, the bioinformatics leader in precision testing has unveiled Quest Lab Stewardship powered by hc1, an innovative new service that employs machine learning to harmonize laboratory testing across health systems in order to help optimize laboratory test utilization. Healthcare system wastes around $765 billion a year, due to factors such as unnecessary or inefficiently delivered services as well as missed prevention opportunities, according to the National Academy of Medicine. Although laboratory testing reflects only about 2-3% of overall health care costs in the United States, ordering lab tests is healthcare's single highest-volume activity.[ii] Under-and overutilization* of lab tests can adversely affect clinical decisions, such as by prompting unnecessary or delayed procedures to address missed diagnoses. Quest Lab Stewardship is the result of a strategic collaboration between Quest and hc1 focused on improving costs and clinical impact of lab testing, in- and out- of hospital settings.

Last year, I posted about Alexa being able used to access complex health information. Microsoft, on the other hand, has taken a different approach to the use of a chatbot/AI for healthcare. Instead of the chatbot being able to access your health record, why not have it answer routine questions patients have prior to an appointment? With this goal in mind, Microsoft has created the Microsoft Healthcare Bot, which is a service that allows healthcare organizations to streamline their processes, and take some of the workload off of their staff. What I like about this service is that it allows for "basic" questions to be answered – issues like clinic hours, when results can be expected, or whether to fast before a blood test, can all be answered. It also has a built-in escalation system, where if a patient needs more information, or if they can't get the answer they need, the AI will pass them on to a person who can answer their questions with the current transcript, ensuring a smooth patient experience.

CAMBRIDGE, MA - 10 Nov 2016: IBM Watson Health (NYSE: IBM) and the Broad Institute of MIT and Harvard today announced a research initiative aimed at discovering the basis of cancer drug resistance. The five year, $50 million project will study thousands of drug resistant tumors and draw on Watson's computational and machine learning methods to help researchers understand how cancers become resistant to therapies. The anonymized data will be made available to the scientific community to catalyze research worldwide. IBM Watson Health and the Broad Institute bring the data prowess of Watson to study cancer drug resistance in a $50M research collaboration. The goal is to identify patterns that could reveal clues into one of the greatest medical mysteries of cancer.

CAMBRIDGE, MA - 10 Nov 2016: IBM Watson Health (NYSE: IBM) and the Broad Institute of MIT and Harvard today announced a research initiative aimed at discovering the basis of cancer drug resistance. The five year, $50 million project will study thousands of drug resistant tumors and draw on Watson's computational and machine learning methods to help researchers understand how cancers become resistant to therapies. The anonymized data will be made available to the scientific community to catalyze research worldwide. To help understand how cancers become resistant to specific therapies, Broad Institute will generate tumor genome sequence data from patients who initially respond to treatment but who then become drug-resistant. Broad will use new genome-editing methods to conduct large-scale cancer drug resistance studies in the laboratory, to help identify tumors' specific vulnerabilities.

Cancer treatments are about to get an injection of cognitive computing. On Tuesday, IBM Watson Health and Quest Diagnostics launched IBM Watson for Genomics--a service that combines Watson's AI capabilities with genomic tumor sequencing to determine the best course of treatment for individual patients. This is the first time Watson for Genomics will be widely available to patients and physicians nationwide, according to a press release, as Quest Diagnostics serves half of US physicians and hospitals. Quest estimates that it will provide this service for thousands of oncologists who provide about 70% of cancer care in the nation. Tumor mutations vary for each individual, and treatment success often depends on how well a physician can match a therapy to a mutation.